★ Analysts see FY2026 revenue reaching $2.9B — +26.2% growth in a single year.
Why Revenue Could Accelerate
01Signatera oncology test volume growth and adoption rates across colorectal, breast, bladder cancer indications - quarterly volume acceleration signals market penetration
02Reimbursement coverage expansions from Medicare MACs, Medicaid programs, and commercial insurers - positive coverage decisions unlock addressable markets worth hundreds of millions
03Clinical trial readouts and peer-reviewed publications validating clinical utility - data from CIRCULATE, BESPOKE, and other studies drive physician adoption
04Average selling price (ASP) trends and payer mix shifts - movement toward higher-reimbursing commercial/Medicare vs cash-pay affects revenue quality
05Operating margin trajectory and path to sustained profitability - investors focus on when operating leverage inflects to consistent positive earnings
growth - The stock attracts growth-oriented investors focused on disruptive healthcare technology with large addressable markets.
Rising interest rates create moderate headwinds through two channels: (1) higher discount rates compress valuation multiples…
Watch on earnings: Signatera test volumes and revenue per test across colorectal, breast, bladder, and lung cancer indications, Medicare and commercial insurance coverage policy updates from MACs, Palmetto GBA, and national payers, Clinical trial milestone achievements from CIRCULATE-Japan, BESPOKE CRC, and other validation studies.
One Sentence Summary:
The bull case is simple: analysts see revenue climbing from $2.9B to $3.5B as signatera oncology test volume growth and adoption rates across colorectal, breast.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.
